세계의 구충제 시장 : 약제 클래스별, 투여 경로별, 표적 병원체별, 용도별, 유통 채널별 - 예측(2025-2030년)

The Anthelmintic Drugs Market was valued at USD 3.30 billion in 2023, expected to reach USD 3.57 billion in 2024, and is projected to grow at a CAGR of 8.02%, to USD 5.68 billion by 2030.

Anthelmintic drugs, essential in treating infections caused by parasitic worms, serve a crucial role in maintaining public health and veterinary sectors. The scope of these drugs encompasses the prevention and treatment of diseases like schistosomiasis, filariasis, and other worm-related conditions affecting both humans and animals. The necessity for these drugs is accentuated by increasing global travel, unregulated use of over-the-counter anthelmintics fostering resistance, and the growing awareness of the importance of animal healthcare. Used predominantly in the agricultural industry and human healthcare facilities, their application ranges from large-scale deworming programs to routine veterinary practices. End-users include hospitals, clinics, pharmaceutical companies, and animal husbandry operations.

Market growth is influenced by factors such as rising incidences of helminthic infections, advancements in drug formulations enhancing efficacy, and strategic collaborations among key players for market expansion. Recent opportunities lie in emerging markets where deworming is becoming an integral part of public health policies, presenting a lucrative landscape for innovative delivery methods and formulations. Extending the outreach to underserved regions and enhancing awareness could significantly boost market penetration. However, challenges persist, including the growing threat of drug resistance, stringent regulatory policies, and potential side effects constraining the development and adoption of new drugs.

The landscape is ripe for innovation, particularly in developing broad-spectrum anthelmintics with reduced resistance tendencies and drugs tailored to specific regional parasites. Emphasizing research that reduces dosage frequency without compromising effectiveness will also be critical. The nature of the market is characterized by substantial research and regulatory investment, requiring businesses to focus on strategic partnerships and continuous innovation. By investing in enhanced molecular research and bioinformatics, companies can anticipate resistance patterns and tailor solutions to meet emerging needs. The key to market success lies in balancing innovation with stringent compliance and market need anticipation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anthelmintic Drugs Market

The Anthelmintic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing pet adoption coupled with rising focus towards maintaining animal health
  • Increasing spending for animal healthcare and wellness
  • Accelerating prevalence of helminthic infections
• Market Restraints
  • High cost of antiparasitic drugs
• Market Opportunities
  • Increasing veterinary healthcare services centers
  • Emergence of anthelmintic drugs as immune modulators in cancer
• Market Challenges
  • Concerns about the development of drug resistance

Porter's Five Forces: A Strategic Tool for Navigating the Anthelmintic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anthelmintic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anthelmintic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anthelmintic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anthelmintic Drugs Market

A detailed market share analysis in the Anthelmintic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anthelmintic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anthelmintic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anthelmintic Drugs Market

A strategic analysis of the Anthelmintic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anthelmintic Drugs Market, highlighting leading vendors and their innovative profiles. These include Aden Healthcare, Anikem Laboratories, Bayer AG, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Cipla Limited, Dechra Pharmaceuticals PLC, Dr.Reddys Laboratories Inc., Edenbridge Pharmaceuticals LLC, GlaxoSmithKline PLC, Green Cross Remedies, Healthy Life Pharma Private Limited, Johnson & Johnson Services, Inc., Kosher Pharmaceuticals, Lineage Therapeutics Inc, Lupin Limited, Mankind Pharma Ltd., McKesson Corporation, Merck & Co., Inc., Norbrook Laboratories Limited, Novartis AG, Sankur Pharmaceuticals Pvt. Ltd, Takeda Pharmaceutical Company Limited, and Virbac S.A..

Market Segmentation & Coverage

This research report categorizes the Anthelmintic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Benzimidazoles and Piperazine.
• Based on Route of Administration, market is studied across Injectable and Oral.
• Based on Target Pathogen, market is studied across Ancylostoma Duodenale, Ascaris Lumbricoides, Enterobius Vermicularis, and Trichuris Trichiura.
• Based on Application, market is studied across Animal and Human. The Human is further studied across Gastrointestinal Infections and Parenchymal Neurocysticercosis.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Veterinary Hospitals & Clinics, and Veterinary Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing pet adoption coupled with rising focus towards maintaining animal

health

• 5.1.1.2. Increasing spending for animal healthcare and wellness
• 5.1.1.3. Accelerating prevalence of helminthic infections
• 5.1.2. Restraints
  • 5.1.2.1. High cost of antiparasitic drugs
• 5.1.3. Opportunities
  • 5.1.3.1. Increasing veterinary healthcare services centers
  • 5.1.3.2. Emergence of anthelmintic drugs as immune modulators in cancer
• 5.1.4. Challenges
  • 5.1.4.1. Concerns about the development of drug resistance
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anthelmintic Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Benzimidazoles
• 6.3. Piperazine

7. Anthelmintic Drugs Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral

8. Anthelmintic Drugs Market, by Target Pathogen

• 8.1. Introduction
• 8.2. Ancylostoma Duodenale
• 8.3. Ascaris Lumbricoides
• 8.4. Enterobius Vermicularis
• 8.5. Trichuris Trichiura

9. Anthelmintic Drugs Market, by Application

• 9.1. Introduction
• 9.2. Animal
• 9.3. Human
  • 9.3.1. Gastrointestinal Infections
  • 9.3.2. Parenchymal Neurocysticercosis

10. Anthelmintic Drugs Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies
• 10.5. Veterinary Hospitals & Clinics
• 10.6. Veterinary Pharmacies

11. Americas Anthelmintic Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Anthelmintic Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Anthelmintic Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aden Healthcare
• 2. Anikem Laboratories
• 3. Bayer AG
• 4. Boehringer Ingelheim International GmbH
• 5. Ceva Sante Animale
• 6. Cipla Limited
• 7. Dechra Pharmaceuticals PLC
• 8. Dr.Reddys Laboratories Inc.
• 9. Edenbridge Pharmaceuticals LLC
• 10. GlaxoSmithKline PLC
• 11. Green Cross Remedies
• 12. Healthy Life Pharma Private Limited
• 13. Johnson & Johnson Services, Inc.
• 14. Kosher Pharmaceuticals
• 15. Lineage Therapeutics Inc
• 16. Lupin Limited
• 17. Mankind Pharma Ltd.
• 18. McKesson Corporation
• 19. Merck & Co., Inc.
• 20. Norbrook Laboratories Limited
• 21. Novartis AG
• 22. Sankur Pharmaceuticals Pvt. Ltd
• 23. Takeda Pharmaceutical Company Limited
• 24. Virbac S.A.